| 1 |
Aricò M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001; 114(4): 761-9.
|
| 2 |
Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25): 2728-38.
|
| 3 |
Jordan MB, Allen CE, Weitzman S, Filipovich AH, McLain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011; 118(15):4041-52.
doi: 10.1182/blood-2011-03-278127
pmid: 21828139
|
| 4 |
Henter JI, Elinder G, Söder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991; 80(4):428-35.
doi: 10.1111/j.1651-2227.1991.tb11878.x
pmid: 2058392
|
| 5 |
Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the H-score, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014; 66(9): 2613-20.
|
| 6 |
Henter JI, Aricò M, Egeler RM, Elinder G, Favara BE, Filipovich AH, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. Med Pediatr Oncol. 1997; 28(5): 342-7.
doi: 10.1002/(sici)1096-911x(199705)28:5<342::aid-mpo3>3.0.co;2-h
pmid: 9121398
|
| 7 |
Marsh RA, Jordan MB, Talano JA, Nichols K, Kumar A, Naqvi A, et al. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: a review of the published experience. Pediatr Blood Cancer. 2017; 64(4). doi: 10.1002/pbc.26308.
|
| 8 |
FDA. FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal). Available at: https://www.fda.gov/Drugs/DrugSafety/ucm605470.htm
|
| 9 |
Zhou JY, Martinez JA, Shen JP. Lamotrigine-induced hemophagocytic lymphohistiocytosis with Takotsubo cardiomyopathy: a case report. J Med Case Rep. 2019; 13(1): 345.
|
| 10 |
Wang CJ, Fan ZQ, He Y, Fang WJ, Sun W, Li ZJ. Analysis of the clinical characteristics of lamotrigine-induced haemophagocytic lymphohistiocytosis. J Clin Pharm Ther. 2022; 47(6): 745-51.
doi: 10.1111/jcpt.13602
pmid: 35023173
|
), Juan Esteban Munoz Eusse1, Alexander Petrie2, Tsui Yuen1
